Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.
Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Patients on semaglutide ( Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Besides Mankind, Natco Pharma, Dr Reddy’s, Sun Pharma and others are already gearing up for launches of weight-loss drugs ...
Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback